IP Library Granted Patent US 10,188,674
Granted Patent B2
US 10,188,674 · App. 14/387,643 · Granted Jan 29, 2019

Parenteral formulations for administering macrolide antibiotics

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,188,674
App. No.
14/387,643
Granted
Jan 29, 2019
Kind
B2
Abstract

Pharmaceutical compositions adapted for the parenteral administration, including intravenous administration, of triazole containing macrolide antibiotics, and methods for their use in the treatment of bacterial, protozoal, and other infections are described herein.

Claims (34)

1. A pharmaceutical composition adapted for intravenous administration, the composition comprising one or more antibiotic compounds and a formulating agent, wherein the formulating agent comprises an amino acid selected from the group consisting of arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, histidine, lysine, ornithine, serine, threonine, tryptophan, and tyrosine, and pharmaceutically acceptable salts thereof, and combinations thereof; and where at least one of the one or more antibiotic compounds is of the formula

or a pharmaceutically acceptable salt thereof, wherein:

R 10 is hydrogen, acyl or a prodrug moiety;

W is H, F, Cl, Br, I, or OH;

A is CH 2 , C(O), C(O)O, C(O)NH, S(O) 2 , S(O) 2 NH, or C(O)NHS(O) 2 ;

B is C 2 -C 10 alkenylene or C 1 -C 10 alkylene; and

C is hydrogen, hydroxy, acyl, acyloxy, sulfonyl, ureido, or carbamoyl, or alkyl, alkoxy, heteroalkyl, heteroalkoxy, aryl, arylalkyl, heteroaryl, or heteroarylalkyl, each of which is optionally substituted.

2. The composition of claim 1 wherein R 10 is hydrogen.

3. The composition of claim 1 wherein W is H or F.

4. The composition of claim 1 wherein W is F.

5. The composition of claim 1 wherein A is CH 2 .

6. The composition of claim 1 wherein B is C 1 -C 10 alkylene.

7. The composition of claim 1 wherein B is (CH 2 ) n , where n is an integer from 1 to 10.

8. The composition of claim 1 wherein B is (CH 2 ) 3 .

9. The composition of claim 1 wherein C is optionally substituted aryl.

10. The composition of claim 1 wherein one of the antibiotic compounds is solithromycin, or a pharmaceutically acceptable salt thereof.

11. The composition of claim 1 wherein the amino acid is selected from the naturally occurring amino acids having the natural L configuration, and pharmaceutically acceptable salts thereof, and combinations thereof.

12. The composition of claim 1 wherein the amino acid is selected from the group consisting of histidine, aspartic acid, glutamic acid, and pharmaceutically acceptable salts of the foregoing, and any combination thereof.

13. The composition of claim 1 wherein the amino acid is histidine or a pharmaceutically acceptable salt thereof, aspartic acid or a pharmaceutically acceptable salt thereof, and glutamic acid or a pharmaceutically acceptable salt thereof, or a combination thereof.

14. The composition of claim 1 further comprising a liquid vehicle.

15. The composition of claim 14 wherein the liquid vehicle contains about 0.9% by weight sodium chloride or less.

16. The composition of claim 14 wherein the liquid vehicle contains about 0.45% by weight sodium chloride or less.

17. The composition of claim 14 wherein the liquid vehicle is substantially free of sodium chloride.

18. The composition of claim 14 wherein the formulation has a pH in the range from about 3.5 to about 6.

19. A kit comprising a composition of claim 1 , and instructions for the preparation of a pharmaceutically acceptable infusion solution thereof.

20. A method for treating a host animal having a bacterial infection, the method comprising the step of administering by intravenous injection to the host animal a therapeutically effective amount of a composition of claim 14 .

21. The composition of claim 10 wherein the amino acid is selected from the naturally occurring amino acids having the L configuration, and pharmaceutically acceptable salts thereof, and combinations thereof.

22. The composition of claim 10 wherein the amino acid is selected from the group consisting of histidine, aspartic acid, glutamic acid, and pharmaceutically acceptable salts of the foregoing, and any combination thereof.

23. The composition of claim 10 wherein the amino acid is histidine or a pharmaceutically acceptable salt thereof, aspartic acid or a pharmaceutically acceptable salt thereof, and glutamic acid or a pharmaceutically acceptable salt thereof, or a combination thereof.

24. The composition of claim 10 further comprising a liquid vehicle that contains about 0.9% by weight sodium chloride or less.

25. The composition of claim 24 wherein the liquid vehicle contains about 0.45% by weight sodium chloride or less.

26. The composition of claim 24 wherein the liquid vehicle is substantially free of sodium chloride.

27. A kit comprising the composition of claim 10 , and instructions for the preparation of a pharmaceutically acceptable infusion solution thereof.

28. A method for treating a host animal having a bacterial infection, the method comprising administering to the host animal a therapeutically effective amount of a composition of claim 24 by intravenous injection.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2019
From: CEMPRA PHARMACEUTICALS, INC.
To: TETARD, INC.
Reel/Frame 050056/0731 →
RELEASE OF SECURITY INTEREST Recorded Jun 4, 2019
From: CORTLAND CAPITAL MARKET SERVICES LLC
To: CEMPRA PHARMACEUTICALS, INC.
Reel/Frame 049363/0706 →
SECURITY INTEREST Recorded Jan 8, 2018
From: MELINTA THERAPEUTICS, INC.; REMPEX PHARMACEUTICALS, INC.; CEMPRA PHARMACEUTICALS, INC.; CEM-102 PHARMACEUTICALS, INC.
To: CORTLAND CAPITAL MARKET SERVICES LLC, AS AGENT
Reel/Frame 045019/0552 →